Details of the Drug Combinations

General Information of This Drug (ID: DM0YZC6)

Drug Name
Fulvestrant   DM0YZC6
Synonyms
Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

522 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Fulvestrant DCK7XSS 10-hydroxycamptothecin Invasive ductal carcinoma (Cell Line: T-47D) [2]
ABIRATERONE + Fulvestrant DCDG7U9 ABIRATERONE Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
ABIRATERONE + Fulvestrant DCPB63D ABIRATERONE Glioblastoma (Cell Line: SNB-75) [3]
ABIRATERONE + Fulvestrant DCQAS4W ABIRATERONE Glioma (Cell Line: SF-268) [3]
ABIRATERONE + Fulvestrant DCGIKHD ABIRATERONE Papillary renal cell carcinoma (Cell Line: ACHN) [3]
ABIRATERONE + Fulvestrant DC5QPFY ABIRATERONE Invasive ductal carcinoma (Cell Line: T-47D) [2]
ABIRATERONE + Fulvestrant DCM8VZG ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [2]
ABIRATERONE + Fulvestrant DCBAHUO ABIRATERONE Adenocarcinoma (Cell Line: OVCAR3) [4]
ABIRATERONE + Fulvestrant DCTQWP7 ABIRATERONE Amelanotic melanoma (Cell Line: M14) [4]
ABIRATERONE + Fulvestrant DCF3SE9 ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
ABIRATERONE + Fulvestrant DCX87AT ABIRATERONE Lung adenocarcinoma (Cell Line: HOP-62) [4]
ABIRATERONE + Fulvestrant DCEX7ZN ABIRATERONE Melanoma (Cell Line: MALME-3M) [4]
ABIRATERONE + Fulvestrant DC6AW0W ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [4]
ABIRATERONE + Fulvestrant DCWPFWD ABIRATERONE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
ABIRATERONE + Fulvestrant DCNA1TR ABIRATERONE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Amonafide + Fulvestrant DCASZ89 Amonafide Adenocarcinoma (Cell Line: DU-145) [3]
Amonafide + Fulvestrant DCA8HHZ Amonafide Adenocarcinoma (Cell Line: HCC-2998) [3]
Amonafide + Fulvestrant DC4VM2A Amonafide Chronic myelogenous leukemia (Cell Line: K-562) [3]
Anastrozole + Fulvestrant DC3U3WB Anastrozole Adenocarcinoma (Cell Line: DU-145) [3]
Anastrozole + Fulvestrant DCE97OY Anastrozole Adenocarcinoma (Cell Line: NCIH23) [3]
Anastrozole + Fulvestrant DCAGODI Anastrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Anastrozole + Fulvestrant DCY47NH Anastrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Anastrozole + Fulvestrant DCPME5Y Anastrozole Amelanotic melanoma (Cell Line: M14) [3]
Anastrozole + Fulvestrant DCRNKSL Anastrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Anastrozole + Fulvestrant DCH5Q1Q Anastrozole Anaplastic large cell lymphoma (Cell Line: SR) [3]
Anastrozole + Fulvestrant DC7JWCI Anastrozole Clear cell renal cell carcinoma (Cell Line: A498) [3]
Anastrozole + Fulvestrant DCK23ZR Anastrozole Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Anastrozole + Fulvestrant DCY4UYX Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Anastrozole + Fulvestrant DCULV1D Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Anastrozole + Fulvestrant DC12J0K Anastrozole Glioma (Cell Line: SF-268) [3]
Anastrozole + Fulvestrant DCZ5EI9 Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Anastrozole + Fulvestrant DCNTOUE Anastrozole Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Anastrozole + Fulvestrant DCJ71DS Anastrozole Lung adenocarcinoma (Cell Line: EKVX) [3]
Anastrozole + Fulvestrant DC8R1GL Anastrozole Malignant melanoma (Cell Line: UACC62) [3]
Anastrozole + Fulvestrant DCMHSW8 Anastrozole Melanoma (Cell Line: MALME-3M) [3]
Anastrozole + Fulvestrant DCM8N9N Anastrozole Melanoma (Cell Line: UACC-257) [3]
Anastrozole + Fulvestrant DCAC7FH Anastrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Anastrozole + Fulvestrant DCY4HKY Anastrozole Prostate carcinoma (Cell Line: PC-3) [3]
Anastrozole + Fulvestrant DCVNJC2 Anastrozole Renal cell carcinoma (Cell Line: SN12C) [3]
Arfolitixorin + Fulvestrant DCSFLOT Arfolitixorin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Azacitidine + Fulvestrant DCNPFQI Azacitidine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Azacitidine + Fulvestrant DC8LLJ4 Azacitidine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Azacitidine + Fulvestrant DC4XQJE Azacitidine Chronic myelogenous leukemia (Cell Line: K-562) [3]
Azacitidine + Fulvestrant DC7SZK4 Azacitidine Clear cell renal cell carcinoma (Cell Line: A498) [3]
Azacitidine + Fulvestrant DCWJMIL Azacitidine Glioma (Cell Line: SF-268) [3]
Azacitidine + Fulvestrant DC8KWFL Azacitidine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Azacitidine + Fulvestrant DCGWSDO Azacitidine Lung adenocarcinoma (Cell Line: HOP-62) [3]
Azacitidine + Fulvestrant DCI1T5H Azacitidine Lung adenocarcinoma (Cell Line: EKVX) [3]
Azacitidine + Fulvestrant DCQVTYR Azacitidine Melanoma (Cell Line: MALME-3M) [3]
Azacitidine + Fulvestrant DCX4CQA Azacitidine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Azacitidine + Fulvestrant DC3KQ0P Azacitidine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
BIO-300 + Fulvestrant DCQMWXJ BIO-300 Chronic myelogenous leukemia (Cell Line: K-562) [3]
BIO-300 + Fulvestrant DCEKSI9 BIO-300 Adenocarcinoma (Cell Line: DU-145) [4]
BIO-300 + Fulvestrant DCCPLYU BIO-300 Adenocarcinoma (Cell Line: HT29) [4]
Cabazitaxel + Fulvestrant DCCWDJR Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [3]
Cabazitaxel + Fulvestrant DC280G1 Cabazitaxel Adenocarcinoma (Cell Line: HT29) [3]
Cabazitaxel + Fulvestrant DCBX5ZE Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [3]
Cabazitaxel + Fulvestrant DCFW7CZ Cabazitaxel Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Cabazitaxel + Fulvestrant DC2X3L3 Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Cabazitaxel + Fulvestrant DC8DEQC Cabazitaxel Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Cabazitaxel + Fulvestrant DCWORKV Cabazitaxel Melanoma (Cell Line: MALME-3M) [3]
Cabazitaxel + Fulvestrant DCM13HU Cabazitaxel Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Cabazitaxel + Fulvestrant DC8SHRR Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [3]
Cabazitaxel + Fulvestrant DCO9WU0 Cabazitaxel Carcinoma (Cell Line: RXF 393) [2]
Cabazitaxel + Fulvestrant DCKJ9N4 Cabazitaxel Carcinoma (Cell Line: MCF7) [2]
Crizotinib + Fulvestrant DCB5QBZ Crizotinib Adenocarcinoma (Cell Line: DU-145) [3]
Crizotinib + Fulvestrant DCPHGWL Crizotinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Crizotinib + Fulvestrant DCB5W68 Crizotinib Adenocarcinoma (Cell Line: NCIH23) [3]
Crizotinib + Fulvestrant DC2HHR3 Crizotinib Amelanotic melanoma (Cell Line: M14) [3]
Crizotinib + Fulvestrant DCG3XGK Crizotinib Astrocytoma (Cell Line: U251) [3]
Crizotinib + Fulvestrant DC7UOWK Crizotinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Crizotinib + Fulvestrant DCWXSRL Crizotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Crizotinib + Fulvestrant DCK2EUS Crizotinib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Crizotinib + Fulvestrant DC8PGMC Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Crizotinib + Fulvestrant DCAK25M Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Crizotinib + Fulvestrant DC21XTR Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Crizotinib + Fulvestrant DCGSS9M Crizotinib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Crizotinib + Fulvestrant DCZ9KV1 Crizotinib Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Crizotinib + Fulvestrant DC0VGDC Crizotinib Melanoma (Cell Line: UACC-257) [3]
Crizotinib + Fulvestrant DC4F8LB Crizotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Crizotinib + Fulvestrant DC3OYU6 Crizotinib Carcinoma (Cell Line: MCF7) [2]
Crizotinib + Fulvestrant DCFEHTU Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [2]
Crizotinib + Fulvestrant DCRWNED Crizotinib Invasive ductal carcinoma (Cell Line: BT-549) [2]
Dacarbazine + Fulvestrant DCD3J5E Dacarbazine Adenocarcinoma (Cell Line: HCT116) [3]
Dacarbazine + Fulvestrant DCRVJ41 Dacarbazine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Dacarbazine + Fulvestrant DCEBU71 Dacarbazine Glioma (Cell Line: SF-268) [3]
Dacarbazine + Fulvestrant DCDV0SJ Dacarbazine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Dacarbazine + Fulvestrant DCMLU26 Dacarbazine Invasive ductal carcinoma (Cell Line: BT-549) [2]
Dactinomycin + Fulvestrant DCNELFL Dactinomycin Carcinoma (Cell Line: RXF 393) [2]
Dactinomycin + Fulvestrant DCDB4F3 Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [2]
Dactinomycin + Fulvestrant DC7TZBV Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [2]
Dactinomycin + Fulvestrant DCIGZ9V Dactinomycin Invasive ductal carcinoma (Cell Line: T-47D) [2]
Dactinomycin + Fulvestrant DCQO2MH Dactinomycin Adenocarcinoma (Cell Line: DU-145) [4]
Dactinomycin + Fulvestrant DC06F6F Dactinomycin Adenocarcinoma (Cell Line: A549) [4]
Dactinomycin + Fulvestrant DCZN79W Dactinomycin Adenocarcinoma (Cell Line: HCT-15) [4]
Dactinomycin + Fulvestrant DCVUJ1W Dactinomycin Adenocarcinoma (Cell Line: HCT116) [4]
Dactinomycin + Fulvestrant DCCPPW2 Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [4]
Dactinomycin + Fulvestrant DCPHF16 Dactinomycin Adenocarcinoma (Cell Line: HT29) [4]
Dactinomycin + Fulvestrant DCDMWZP Dactinomycin Astrocytoma (Cell Line: U251) [4]
Dactinomycin + Fulvestrant DC1PT6C Dactinomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Dactinomycin + Fulvestrant DC66YDI Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Dactinomycin + Fulvestrant DCV1CHT Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Dactinomycin + Fulvestrant DCQGRCS Dactinomycin Glioblastoma (Cell Line: SNB-75) [4]
Dactinomycin + Fulvestrant DCAY0TC Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Dactinomycin + Fulvestrant DC6DO3W Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Dactinomycin + Fulvestrant DC98EL0 Dactinomycin Malignant melanoma (Cell Line: UACC62) [4]
Dactinomycin + Fulvestrant DCSHAH4 Dactinomycin Melanoma (Cell Line: UACC-257) [4]
Dactinomycin + Fulvestrant DC8BHA0 Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Dactinomycin + Fulvestrant DCYJDX3 Dactinomycin Prostate carcinoma (Cell Line: PC-3) [4]
Dactinomycin + Fulvestrant DC0DR0I Dactinomycin Renal cell carcinoma (Cell Line: UO-31) [4]
Dasatinib + Fulvestrant DCTAQOU Dasatinib Adenocarcinoma (Cell Line: HT29) [3]
Dasatinib + Fulvestrant DCWQTIR Dasatinib Amelanotic melanoma (Cell Line: M14) [3]
Dasatinib + Fulvestrant DC96B9K Dasatinib Glioma (Cell Line: SF-268) [3]
Dasatinib + Fulvestrant DC7S0GY Dasatinib Glioma (Cell Line: SF-539) [3]
Dasatinib + Fulvestrant DC69PKF Dasatinib Glioma (Cell Line: SF-295) [3]
Dasatinib + Fulvestrant DCEMG8S Dasatinib Malignant melanoma (Cell Line: LOX IMVI) [3]
Dasatinib + Fulvestrant DCAEY0U Dasatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Dasatinib + Fulvestrant DCPLXRI Dasatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Dexrazoxane + Fulvestrant DCSJSQ1 Dexrazoxane Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Dexrazoxane + Fulvestrant DC6RWLM Dexrazoxane Anaplastic large cell lymphoma (Cell Line: SR) [3]
Dexrazoxane + Fulvestrant DCP5SGC Dexrazoxane Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Dexrazoxane + Fulvestrant DCM2ER6 Dexrazoxane Colon adenocarcinoma (Cell Line: COLO 205) [2]
Dexrazoxane + Fulvestrant DCKDUPT Dexrazoxane Adenocarcinoma (Cell Line: HCT116) [4]
Dexrazoxane + Fulvestrant DCYOH6G Dexrazoxane Large cell lung carcinoma (Cell Line: NCI-H460) [4]
DFN-15 + Fulvestrant DC1I3Y7 DFN-15 Glioma (Cell Line: SF-539) [3]
DFN-15 + Fulvestrant DC1KIK5 DFN-15 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
DFN-15 + Fulvestrant DCNOTA7 DFN-15 Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Fulvestrant DCA3Y4Z Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Epirubicin + Fulvestrant DCCQ53E Epirubicin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Epirubicin + Fulvestrant DCJNTWP Epirubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Epirubicin + Fulvestrant DCQNNWN Epirubicin Glioma (Cell Line: SF-268) [3]
Epirubicin + Fulvestrant DC44OOK Epirubicin Invasive ductal carcinoma (Cell Line: T-47D) [2]
Epirubicin + Fulvestrant DCDGKF3 Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [2]
Epirubicin + Fulvestrant DCHCHRW Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [2]
Epirubicin + Fulvestrant DCRM4HG Epirubicin Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Fulvestrant DCYX838 Epirubicin Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Fulvestrant DC1O3DY Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Fulvestrant DC56NNV Epirubicin Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Fulvestrant DCNU8VE Epirubicin Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Fulvestrant DCTWIRF Epirubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Fulvestrant DCC6BHG Epirubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Estramustine + Fulvestrant DCFWXBJ Estramustine Renal cell carcinoma (Cell Line: SN12C) [3]
Estramustine + Fulvestrant DCUBQ1P Estramustine Adenocarcinoma (Cell Line: HCC-2998) [4]
Estramustine + Fulvestrant DC4NTFJ Estramustine Lung adenocarcinoma (Cell Line: EKVX) [4]
Fulvestrant + Pentostatin DCE2NSP Pentostatin Adenocarcinoma (Cell Line: HCT-15) [3]
Fulvestrant + Pentostatin DCGZH6V Pentostatin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fulvestrant + Pentostatin DCHGK6P Pentostatin Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Fulvestrant + Pentostatin DCE2FBZ Pentostatin Lung adenocarcinoma (Cell Line: EKVX) [3]
Fulvestrant + Pentostatin DCTRKMQ Pentostatin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Fulvestrant + Hepzato DC30Q34 Hepzato Adenocarcinoma (Cell Line: HT29) [3]
Fulvestrant + Hepzato DC96SIG Hepzato Glioma (Cell Line: SF-295) [3]
Fulvestrant + Hepzato DCG3O4U Hepzato Glioma (Cell Line: SF-539) [3]
Fulvestrant + Hepzato DC9WXUK Hepzato Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Fulvestrant + Ixabepilone DCWU6S5 Ixabepilone Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fulvestrant + Ixabepilone DCWLGP7 Ixabepilone Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fulvestrant + Ixabepilone DCS2YAP Ixabepilone Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Fulvestrant + Cyclophosphamide DCRBQ9A Cyclophosphamide Adenocarcinoma (Cell Line: HCC-2998) [3]
Fulvestrant + Cyclophosphamide DCRD17D Cyclophosphamide Adenocarcinoma (Cell Line: HT29) [3]
Fulvestrant + Cyclophosphamide DCKKHKK Cyclophosphamide Malignant melanoma (Cell Line: UACC62) [3]
Fulvestrant + Cyclophosphamide DCRJMWD Cyclophosphamide Melanoma (Cell Line: MALME-3M) [3]
Fulvestrant + Cyclophosphamide DCXNDI2 Cyclophosphamide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Fulvestrant + Cyclophosphamide DCL8EC5 Cyclophosphamide Prostate carcinoma (Cell Line: PC-3) [3]
Fulvestrant + Panobinostat DCJ47WF Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Fulvestrant + Methotrexate DCLURX1 Methotrexate Melanoma (Cell Line: MALME-3M) [3]
Fulvestrant + Isoniazid DCLOSJ1 Isoniazid Adenocarcinoma (Cell Line: HT29) [3]
Fulvestrant + Isoniazid DCZ23K5 Isoniazid Adenocarcinoma (Cell Line: HCT116) [3]
Fulvestrant + Isoniazid DCCDEQ2 Isoniazid Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Fulvestrant + Isoniazid DCSQSIC Isoniazid High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Fulvestrant + Isoniazid DC2HSE6 Isoniazid Renal cell carcinoma (Cell Line: UO-31) [3]
Fulvestrant + Arsenic trioxide DCJ5A45 Arsenic trioxide Adenocarcinoma (Cell Line: HCT116) [3]
Fulvestrant + Arsenic trioxide DCJW5YB Arsenic trioxide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fulvestrant + Arsenic trioxide DCX8VF1 Arsenic trioxide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Fulvestrant + Arsenic trioxide DCHOM2A Arsenic trioxide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Fulvestrant + 10-hydroxycamptothecin DC9WV0O 10-hydroxycamptothecin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Fulvestrant + 10-hydroxycamptothecin DC2TWJK 10-hydroxycamptothecin Renal cell carcinoma (Cell Line: SN12C) [3]
Fulvestrant + Pralatrexate DCFFYHB Pralatrexate Adenocarcinoma (Cell Line: SW-620) [3]
Fulvestrant + Ifosfamide DC0993L Ifosfamide Adenocarcinoma (Cell Line: OVCAR3) [3]
Fulvestrant + Ifosfamide DCI0BTZ Ifosfamide Adenocarcinoma (Cell Line: HCT116) [3]
Fulvestrant + Ifosfamide DC1JNLF Ifosfamide Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fulvestrant + Ifosfamide DCIU1Z1 Ifosfamide Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Fulvestrant + Ifosfamide DCEJVOS Ifosfamide Glioma (Cell Line: SF-268) [3]
Fulvestrant + Ifosfamide DCNECO5 Ifosfamide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Fulvestrant + Ifosfamide DCWQ8HM Ifosfamide Melanoma (Cell Line: SK-MEL-2) [3]
Fulvestrant + Docetaxel DCJU91O Docetaxel Adenocarcinoma (Cell Line: DU-145) [3]
Fulvestrant + Docetaxel DCX14J4 Docetaxel Adenocarcinoma (Cell Line: OVCAR3) [3]
Fulvestrant + Docetaxel DCMXRJN Docetaxel Adenocarcinoma (Cell Line: NCIH23) [3]
Fulvestrant + Docetaxel DCBS161 Docetaxel Adenocarcinoma (Cell Line: A549) [3]
Fulvestrant + Docetaxel DCBGP2P Docetaxel Adenocarcinoma (Cell Line: HT29) [3]
Fulvestrant + Docetaxel DC33QHU Docetaxel Adenocarcinoma (Cell Line: HCT116) [3]
Fulvestrant + Docetaxel DC5EEFN Docetaxel Adenocarcinoma (Cell Line: SW-620) [3]
Fulvestrant + Docetaxel DCN0Y39 Docetaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fulvestrant + Docetaxel DCY7ICB Docetaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Fulvestrant + Docetaxel DCH7DLU Docetaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Fulvestrant + Docetaxel DC8POLS Docetaxel Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fulvestrant + Docetaxel DC1PQHT Docetaxel Astrocytoma (Cell Line: U251) [3]
Fulvestrant + Docetaxel DC5OZGE Docetaxel Astrocytoma (Cell Line: SNB-19) [3]
Fulvestrant + Docetaxel DC221RR Docetaxel Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fulvestrant + Docetaxel DCKQ47I Docetaxel Clear cell renal cell carcinoma (Cell Line: A498) [3]
Fulvestrant + Docetaxel DCOIPO2 Docetaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Fulvestrant + Docetaxel DCU1X4B Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Fulvestrant + Docetaxel DC68VUF Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Fulvestrant + Docetaxel DCAE6R3 Docetaxel Glioma (Cell Line: SF-539) [3]
Fulvestrant + Docetaxel DC0G8W7 Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Fulvestrant + Docetaxel DCZM47C Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Fulvestrant + Docetaxel DC5BV1M Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Fulvestrant + Docetaxel DCOBXV7 Docetaxel Lung adenocarcinoma (Cell Line: EKVX) [3]
Fulvestrant + Docetaxel DC0V8MT Docetaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Fulvestrant + Docetaxel DC7YSSV Docetaxel Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Fulvestrant + Docetaxel DCN5C7M Docetaxel Malignant melanoma (Cell Line: UACC62) [3]
Fulvestrant + Docetaxel DCUHMH5 Docetaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Fulvestrant + Docetaxel DCFQL4P Docetaxel Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Fulvestrant + Docetaxel DC5MNY4 Docetaxel Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Fulvestrant + Docetaxel DCF52CA Docetaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Fulvestrant + Docetaxel DC6ZF04 Docetaxel Renal cell carcinoma (Cell Line: SN12C) [3]
Fulvestrant + Raloxifene DC9C8O9 Raloxifene Amelanotic melanoma (Cell Line: M14) [3]
Fulvestrant + Raloxifene DC9JFJ7 Raloxifene Astrocytoma (Cell Line: SNB-19) [3]
Fulvestrant + Raloxifene DCKPL8K Raloxifene Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Fulvestrant + Raloxifene DCHX40Z Raloxifene Clear cell renal cell carcinoma (Cell Line: A498) [3]
Fulvestrant + Raloxifene DCBXJJ3 Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Fulvestrant + Raloxifene DCUUFAA Raloxifene Malignant melanoma (Cell Line: UACC62) [3]
Fulvestrant + Mitomycin DCSPOPV Mitomycin Melanoma (Cell Line: MALME-3M) [3]
Fulvestrant + Mitomycin DCJZG0L Mitomycin Renal cell carcinoma (Cell Line: UO-31) [3]
Fulvestrant + Altretamine DCNS7IB Altretamine Glioma (Cell Line: SF-268) [3]
Fulvestrant + Altretamine DCN9JMD Altretamine Malignant melanoma (Cell Line: UACC62) [3]
Fulvestrant + Altretamine DCCCW71 Altretamine Renal cell carcinoma (Cell Line: UO-31) [3]
Fulvestrant + TEM DC58OY1 TEM Renal cell carcinoma (Cell Line: UO-31) [3]
Fulvestrant + TEM DCM41XV TEM Renal cell carcinoma (Cell Line: SN12C) [3]
Fulvestrant + Idarubicin DC69KIW Idarubicin Glioblastoma? (Cell Line: T98G) [3]
Fulvestrant + Bortezomib DCMOIAW Bortezomib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fulvestrant + Cisplatin DCO3GIX Cisplatin Melanoma (Cell Line: SK-MEL-2) [3]
Fulvestrant + Chlorambucil DCCHC9R Chlorambucil Adenocarcinoma (Cell Line: HT29) [3]
Fulvestrant + Chlorambucil DCLDDO6 Chlorambucil Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fulvestrant + Chlorambucil DC420QR Chlorambucil Glioblastoma (Cell Line: SNB-75) [3]
Fulvestrant + Chlorambucil DCDE88O Chlorambucil Glioma (Cell Line: SF-295) [3]
Fulvestrant + Chlorambucil DCJ5UVU Chlorambucil High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Fulvestrant + Chlorambucil DC42W7T Chlorambucil Lung adenocarcinoma (Cell Line: HOP-62) [3]
Fulvestrant + Chlorambucil DC1GZ1V Chlorambucil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Fulvestrant + Chlorambucil DC6C050 Chlorambucil Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Fulvestrant + Sorafenib DCLEX4Q Sorafenib Adenocarcinoma (Cell Line: HCT-15) [3]
Fulvestrant + Sorafenib DC067S7 Sorafenib Adenocarcinoma (Cell Line: HT29) [3]
Fulvestrant + Sorafenib DCSHOXE Sorafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fulvestrant + Sorafenib DC7R09K Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Fulvestrant + Sorafenib DC48XDT Sorafenib Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Fulvestrant + Sorafenib DCKLE8M Sorafenib Melanoma (Cell Line: SK-MEL-2) [3]
Fulvestrant + ER819762 DCNHJI0 ER819762 Adenocarcinoma (Cell Line: A549) [3]
Fulvestrant + ER819762 DCV3QR5 ER819762 Adenocarcinoma (Cell Line: HCC-2998) [3]
Fulvestrant + ER819762 DCOWXYF ER819762 Adenocarcinoma (Cell Line: HCT-15) [3]
Fulvestrant + ER819762 DC4JZGT ER819762 Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fulvestrant + ER819762 DCBKZGP ER819762 Clear cell renal cell carcinoma (Cell Line: A498) [3]
Fulvestrant + ER819762 DC6FDQC ER819762 Melanoma (Cell Line: SK-MEL-2) [3]
Fulvestrant + ER819762 DCYFPZN ER819762 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Fulvestrant + ER819762 DCLD8OR ER819762 Prostate carcinoma (Cell Line: PC-3) [3]
Fulvestrant + Pomalidomide DCXSGPQ Pomalidomide Astrocytoma (Cell Line: SNB-19) [3]
Fulvestrant + Pomalidomide DCBTO8I Pomalidomide Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Fulvestrant + Pomalidomide DCNXEO9 Pomalidomide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Fulvestrant + Pomalidomide DCYSK0D Pomalidomide Melanoma (Cell Line: MALME-3M) [3]
Fulvestrant + Mepacrine DC1J6C4 Mepacrine Adenocarcinoma (Cell Line: OVCAR3) [3]
Fulvestrant + Mepacrine DCV633L Mepacrine Adenocarcinoma (Cell Line: HCT-15) [3]
Fulvestrant + PMID28870136-Compound-43 DCDHGJY PMID28870136-Compound-43 Adenocarcinoma (Cell Line: OVCAR3) [3]
Fulvestrant + PMID28870136-Compound-43 DC4UC2Y PMID28870136-Compound-43 Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Fulvestrant + PMID28870136-Compound-43 DCSGHMD PMID28870136-Compound-43 Glioma (Cell Line: SF-539) [3]
Fulvestrant + FORMESTANE DCCN3FN FORMESTANE Adenocarcinoma (Cell Line: OVCAR3) [3]
Fulvestrant + FORMESTANE DC08VW4 FORMESTANE Malignant melanoma (Cell Line: LOX IMVI) [3]
Fulvestrant + FORMESTANE DC391GH FORMESTANE Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Fulvestrant + FORMESTANE DCII7H9 FORMESTANE Renal cell carcinoma (Cell Line: UO-31) [3]
Fulvestrant + Aminolevulinic Acid Hydrochloride DCYTBMP Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: DU-145) [3]
Fulvestrant + Aminolevulinic Acid Hydrochloride DCR5K5S Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: A549) [3]
Fulvestrant + Aminolevulinic Acid Hydrochloride DCL75SL Aminolevulinic Acid Hydrochloride Melanoma (Cell Line: MALME-3M) [3]
Fulvestrant + Busulfan DCWUCSZ Busulfan Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Fulvestrant + Busulfan DCZ7W81 Busulfan Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Fulvestrant + Pentostatin DCNN6A6 Pentostatin Invasive ductal carcinoma (Cell Line: HS 578T) [2]
Fulvestrant + Ixabepilone DCJE447 Ixabepilone Breast adenocarcinoma (Cell Line: MDA-MB-468) [2]
Fulvestrant + Ixabepilone DCWZUNA Ixabepilone Colon adenocarcinoma (Cell Line: COLO 205) [2]
Fulvestrant + Methotrexate DC2ITL1 Methotrexate Invasive ductal carcinoma (Cell Line: T-47D) [2]
Fulvestrant + Docetaxel DCRAHQB Docetaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [2]
Fulvestrant + Docetaxel DCQE7FZ Docetaxel Carcinoma (Cell Line: MCF7) [2]
Fulvestrant + Docetaxel DCKZXZ6 Docetaxel Colon adenocarcinoma (Cell Line: COLO 205) [2]
Fulvestrant + Docetaxel DCZICAX Docetaxel Colon carcinoma (Cell Line: KM12) [2]
Fulvestrant + Raloxifene DCV89Z4 Raloxifene Invasive ductal carcinoma (Cell Line: BT-549) [2]
Fulvestrant + Altretamine DCHX3SB Altretamine Invasive ductal carcinoma (Cell Line: T-47D) [2]
Fulvestrant + Altretamine DCBO9DT Altretamine Invasive ductal carcinoma (Cell Line: HS 578T) [2]
Fulvestrant + TEM DCI48WJ TEM Carcinoma (Cell Line: RXF 393) [2]
Fulvestrant + Bortezomib DC9ANP3 Bortezomib Colon adenocarcinoma (Cell Line: COLO 205) [2]
Fulvestrant + Bortezomib DCN5T0X Bortezomib Invasive ductal carcinoma (Cell Line: T-47D) [2]
Fulvestrant + Chlorambucil DC0EW6M Chlorambucil Carcinoma (Cell Line: MCF7) [2]
Fulvestrant + Chlorambucil DC6GLB1 Chlorambucil Colon carcinoma (Cell Line: KM12) [2]
Fulvestrant + ER819762 DCMCQO3 ER819762 Invasive ductal carcinoma (Cell Line: T-47D) [2]
Fulvestrant + Mepacrine DCBMXGC Mepacrine Invasive ductal carcinoma (Cell Line: T-47D) [2]
Fulvestrant + FORMESTANE DC441YS FORMESTANE Breast adenocarcinoma (Cell Line: MDA-MB-468) [2]
Gefitinib + Fulvestrant DCYN0TA Gefitinib Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Fulvestrant DCWP914 Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Fulvestrant DCDWRYK Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Fulvestrant DCB7IGH Gefitinib Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Fulvestrant DCX0AGX Gefitinib Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Hepzato + Fulvestrant DCW2ZY2 Hepzato Renal cell carcinoma (Cell Line: UO-31) [3]
Hepzato + Fulvestrant DC9NWNI Hepzato Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Idarubicin + Fulvestrant DCNXINP Idarubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Idarubicin + Fulvestrant DC7IPU4 Idarubicin Colon adenocarcinoma (Cell Line: COLO 205) [2]
Idarubicin + Fulvestrant DCZAIIA Idarubicin Malignant melanoma (Cell Line: LOX IMVI) [4]
Imatinib + Fulvestrant DC51RE0 Imatinib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Indazole derivative 5 + Fulvestrant DC52X6V Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Indazole derivative 5 + Fulvestrant DCPSQT0 Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [3]
Indazole derivative 5 + Fulvestrant DC9FEG2 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Indazole derivative 5 + Fulvestrant DC5LOGL Indazole derivative 5 Carcinoma (Cell Line: RXF 393) [2]
Indazole derivative 5 + Fulvestrant DC63X0Q Indazole derivative 5 Carcinoma (Cell Line: MCF7) [2]
Indazole derivative 5 + Fulvestrant DC9GJFF Indazole derivative 5 Colon adenocarcinoma (Cell Line: COLO 205) [2]
Indazole derivative 5 + Fulvestrant DCTR96X Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [2]
Indazole derivative 5 + Fulvestrant DCPIDBQ Indazole derivative 5 Adenocarcinoma (Cell Line: DU-145) [4]
Indazole derivative 5 + Fulvestrant DCG9COC Indazole derivative 5 Adenocarcinoma (Cell Line: OVCAR3) [4]
Indazole derivative 5 + Fulvestrant DCVY30W Indazole derivative 5 Adenocarcinoma (Cell Line: NCIH23) [4]
Indazole derivative 5 + Fulvestrant DC3PXBF Indazole derivative 5 Amelanotic melanoma (Cell Line: M14) [4]
Indazole derivative 5 + Fulvestrant DCT23DT Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Indazole derivative 5 + Fulvestrant DCORU04 Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Indazole derivative 5 + Fulvestrant DCRVS3D Indazole derivative 5 Malignant melanoma (Cell Line: LOX IMVI) [4]
Indazole derivative 5 + Fulvestrant DCJ253K Indazole derivative 5 Melanoma (Cell Line: MALME-3M) [4]
Indazole derivative 5 + Fulvestrant DC72BWZ Indazole derivative 5 Melanoma (Cell Line: UACC-257) [4]
Indazole derivative 5 + Fulvestrant DCNVEW5 Indazole derivative 5 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
JNK-IN-8 + Fulvestrant DCOEBRZ JNK-IN-8 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Lapatinib + Fulvestrant DCEXSG5 Lapatinib Invasive ductal carcinoma (Cell Line: HS 578T) [2]
Lapatinib + Fulvestrant DC7YNQ6 Lapatinib Adenocarcinoma (Cell Line: SW-620) [4]
Lenalidomide + Fulvestrant DCHDW0N Lenalidomide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Lenalidomide + Fulvestrant DC3AK70 Lenalidomide Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Lenalidomide + Fulvestrant DCJK0B4 Lenalidomide Adenocarcinoma (Cell Line: NCIH23) [4]
Lenalidomide + Fulvestrant DC08HY7 Lenalidomide Adenocarcinoma (Cell Line: HCC-2998) [4]
Lenalidomide + Fulvestrant DCC0NYI Lenalidomide Melanoma (Cell Line: UACC-257) [4]
Letrozole + Fulvestrant DCSODBJ Letrozole Adenocarcinoma (Cell Line: HCC-2998) [3]
Letrozole + Fulvestrant DCX45KO Letrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Letrozole + Fulvestrant DC9G1DO Letrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
LIAROZOLE + Fulvestrant DCLETOC LIAROZOLE Glioma (Cell Line: SF-268) [3]
LIAROZOLE + Fulvestrant DCSMMG2 LIAROZOLE Melanoma (Cell Line: UACC-257) [4]
Mechlorethamine + Fulvestrant DCIL5UE Mechlorethamine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Nilotinib + Fulvestrant DCZLFA3 Nilotinib Glioma (Cell Line: SF-539) [3]
Nilotinib + Fulvestrant DCPAPFJ Nilotinib Colon carcinoma (Cell Line: KM12) [2]
Nilotinib + Fulvestrant DCQLU8Q Nilotinib Invasive ductal carcinoma (Cell Line: T-47D) [2]
Nilotinib + Fulvestrant DC7JT0W Nilotinib Invasive ductal carcinoma (Cell Line: HS 578T) [2]
Nilotinib + Fulvestrant DC8KFD2 Nilotinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Nilotinib + Fulvestrant DC7DEIQ Nilotinib Adenocarcinoma (Cell Line: HCC-2998) [4]
Nilotinib + Fulvestrant DCAJQY9 Nilotinib Adenocarcinoma (Cell Line: HCT-15) [4]
Plicamycin + Fulvestrant DCOZ38Q Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Plicamycin + Fulvestrant DCXNNAO Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Plicamycin + Fulvestrant DCITX3Q Plicamycin Renal cell carcinoma (Cell Line: SN12C) [3]
Plicamycin + Fulvestrant DCQYCF5 Plicamycin Renal cell carcinoma (Cell Line: UO-31) [3]
Plicamycin + Fulvestrant DC46Z5A Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [2]
Plicamycin + Fulvestrant DCQDC2O Plicamycin Adenocarcinoma (Cell Line: OVCAR3) [4]
Plicamycin + Fulvestrant DCZM37A Plicamycin Adenocarcinoma (Cell Line: A549) [4]
Plicamycin + Fulvestrant DCIQAMR Plicamycin Adenocarcinoma (Cell Line: HCT116) [4]
Plicamycin + Fulvestrant DCI5DU6 Plicamycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Plicamycin + Fulvestrant DCETH02 Plicamycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
PMID28460551-Compound-2 + Fulvestrant DCH7X6J PMID28460551-Compound-2 Chronic myelogenous leukemia (Cell Line: K-562) [3]
PMID28460551-Compound-2 + Fulvestrant DCTAH28 PMID28460551-Compound-2 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
PMID28460551-Compound-2 + Fulvestrant DCSVZVO PMID28460551-Compound-2 Colon adenocarcinoma (Cell Line: COLO 205) [2]
PMID28460551-Compound-2 + Fulvestrant DCPE3PC PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DU-145) [4]
PMID28460551-Compound-2 + Fulvestrant DC40EAO PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH23) [4]
PMID28460551-Compound-2 + Fulvestrant DC3JE5B PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [4]
PMID28460551-Compound-2 + Fulvestrant DC2AM1R PMID28460551-Compound-2 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
PMID28460551-Compound-2 + Fulvestrant DC39RQL PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [4]
PMID28460551-Compound-2 + Fulvestrant DC87MA5 PMID28460551-Compound-2 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
PMID28460551-Compound-2 + Fulvestrant DCD4C7L PMID28460551-Compound-2 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Raloxifene + Fulvestrant DCYVVEQ Raloxifene Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Raloxifene + Fulvestrant DCOA82U Raloxifene Glioma (Cell Line: SF-268) [3]
Raloxifene + Fulvestrant DCLQPFO Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Raloxifene + Fulvestrant DCIOFQF Raloxifene Colon adenocarcinoma (Cell Line: COLO 205) [2]
Raloxifene + Fulvestrant DCWN5VK Raloxifene Invasive ductal carcinoma (Cell Line: T-47D) [2]
Raloxifene + Fulvestrant DCZLP8G Raloxifene Invasive ductal carcinoma (Cell Line: BT-549) [2]
Raloxifene + Fulvestrant DCM8G02 Raloxifene Adenocarcinoma (Cell Line: SW-620) [4]
Raloxifene + Fulvestrant DC37295 Raloxifene Adenocarcinoma (Cell Line: HCT-15) [4]
Raloxifene + Fulvestrant DCMO2A2 Raloxifene Amelanotic melanoma (Cell Line: M14) [4]
Raloxifene + Fulvestrant DCFCRPU Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Raloxifene + Fulvestrant DCEMQKH Raloxifene Lung adenocarcinoma (Cell Line: HOP-62) [4]
Raloxifene + Fulvestrant DCCW9KG Raloxifene Melanoma (Cell Line: SK-MEL-2) [4]
Raloxifene + Fulvestrant DCIUHHM Raloxifene Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Raloxifene + Fulvestrant DC857G6 Raloxifene Prostate carcinoma (Cell Line: PC-3) [4]
Romidepsin + Fulvestrant DCJB4H3 Romidepsin Adenocarcinoma (Cell Line: HT29) [4]
Ruxolitinib + Fulvestrant DCPCZZH Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Ruxolitinib + Fulvestrant DCD37IY Ruxolitinib Glioma (Cell Line: SF-268) [3]
Ruxolitinib + Fulvestrant DC81LPK Ruxolitinib Carcinoma (Cell Line: MCF7) [2]
Ruxolitinib + Fulvestrant DCOI5F1 Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [2]
Ruxolitinib + Fulvestrant DCB2OT2 Ruxolitinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Ruxolitinib + Fulvestrant DCGZV5Z Ruxolitinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Ruxolitinib + Fulvestrant DC5PCPA Ruxolitinib Melanoma (Cell Line: SK-MEL-2) [4]
Ruxolitinib + Fulvestrant DCHF2HM Ruxolitinib Melanoma (Cell Line: UACC-257) [4]
Ruxolitinib + Fulvestrant DCD8NGM Ruxolitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Ruxolitinib + Fulvestrant DCJ47YE Ruxolitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
SCH 727965 + Fulvestrant DCICTVU SCH 727965 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
SCH 727965 + Fulvestrant DCZ0200 SCH 727965 Glioma (Cell Line: SF-268) [3]
SCH 727965 + Fulvestrant DCLDDXZ SCH 727965 Renal cell carcinoma (Cell Line: UO-31) [3]
SCH 727965 + Fulvestrant DCHVDZN SCH 727965 Invasive ductal carcinoma (Cell Line: BT-549) [2]
SCH 727965 + Fulvestrant DCMK4D7 SCH 727965 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
SCH 727965 + Fulvestrant DCH5W2A SCH 727965 Malignant melanoma (Cell Line: LOX IMVI) [4]
SCH 727965 + Fulvestrant DC2CA14 SCH 727965 Melanoma (Cell Line: UACC-257) [4]
Sirolimus + Fulvestrant DC2BZ36 Sirolimus Glioma (Cell Line: SF-268) [3]
Sirolimus + Fulvestrant DC0MZT9 Sirolimus Invasive ductal carcinoma (Cell Line: T-47D) [2]
Sirolimus + Fulvestrant DCUT9KF Sirolimus Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Sirolimus + Fulvestrant DCL8VMH Sirolimus Malignant melanoma (Cell Line: UACC62) [4]
Sirolimus + Fulvestrant DCEU5R1 Sirolimus Malignant melanoma (Cell Line: LOX IMVI) [4]
SY-1425 + Fulvestrant DCMBB1M SY-1425 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
SY-1425 + Fulvestrant DCS2ZVS SY-1425 Astrocytoma (Cell Line: U251) [3]
SY-1425 + Fulvestrant DC9NP7P SY-1425 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
SY-1425 + Fulvestrant DCR298D SY-1425 Papillary renal cell carcinoma (Cell Line: ACHN) [3]
SY-1425 + Fulvestrant DCHQMHM SY-1425 Carcinoma (Cell Line: RXF 393) [2]
SY-1425 + Fulvestrant DCG1BA6 SY-1425 Invasive ductal carcinoma (Cell Line: HS 578T) [2]
SY-1425 + Fulvestrant DCHP05W SY-1425 Invasive ductal carcinoma (Cell Line: BT-549) [2]
SY-1425 + Fulvestrant DCAL07K SY-1425 Adenocarcinoma (Cell Line: DU-145) [4]
SY-1425 + Fulvestrant DC1WTFM SY-1425 Adenocarcinoma (Cell Line: NCIH23) [4]
SY-1425 + Fulvestrant DCIMQH4 SY-1425 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
SY-1425 + Fulvestrant DCV5FVJ SY-1425 Malignant melanoma (Cell Line: LOX IMVI) [4]
SY-1425 + Fulvestrant DCHJG58 SY-1425 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Taxol + Fulvestrant DCHUH7F Taxol Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Taxol + Fulvestrant DCZFB7O Taxol Adenocarcinoma (Cell Line: HCC-2998) [4]
Taxol + Fulvestrant DCUELK7 Taxol Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Taxol + Fulvestrant DCRIRXM Taxol Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Taxol + Fulvestrant DC13J0J Taxol Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Terameprocol + Fulvestrant DC065BH Terameprocol Glioblastoma (Cell Line: SNB-75) [3]
Terameprocol + Fulvestrant DCTRYUH Terameprocol Breast adenocarcinoma (Cell Line: MDA-MB-468) [2]
Terameprocol + Fulvestrant DC24LZN Terameprocol Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Terameprocol + Fulvestrant DC8XQBZ Terameprocol Malignant melanoma (Cell Line: LOX IMVI) [4]
Thioguanine + Fulvestrant DCORW1R Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Thioguanine + Fulvestrant DCH2DGM Thioguanine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Thioguanine + Fulvestrant DCSZAIT Thioguanine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Thioguanine + Fulvestrant DC80W0N Thioguanine Renal cell carcinoma (Cell Line: SN12C) [3]
Thioguanine + Fulvestrant DCSV01F Thioguanine Colon adenocarcinoma (Cell Line: COLO 205) [2]
Thioguanine + Fulvestrant DC6EYVZ Thioguanine Adenocarcinoma (Cell Line: NCIH23) [4]
Thioguanine + Fulvestrant DC0EWZ7 Thioguanine Adenocarcinoma (Cell Line: HCT116) [4]
Thioguanine + Fulvestrant DC2FG06 Thioguanine Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Thioguanine + Fulvestrant DCNH573 Thioguanine Lung adenocarcinoma (Cell Line: HOP-62) [4]
Thioguanine + Fulvestrant DCDW6NC Thioguanine Prostate carcinoma (Cell Line: PC-3) [4]
Topotecan + Fulvestrant DC96C9E Topotecan Carcinoma (Cell Line: MCF7) [2]
Topotecan + Fulvestrant DCDIGJD Topotecan Adenocarcinoma (Cell Line: DU-145) [4]
Topotecan + Fulvestrant DCYCKWD Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Topotecan + Fulvestrant DC5AP68 Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Topotecan + Fulvestrant DC7LUGN Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Topotecan + Fulvestrant DCW7HGT Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Topotecan + Fulvestrant DCP4V87 Topotecan Glioma (Cell Line: SF-268) [4]
Topotecan + Fulvestrant DCGO9UQ Topotecan Melanoma (Cell Line: UACC-257) [4]
Topotecan + Fulvestrant DCAP53I Topotecan Melanoma (Cell Line: MALME-3M) [4]
Topotecan + Fulvestrant DC266TN Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Topotecan + Fulvestrant DCJNUDL Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Topotecan + Fulvestrant DC1RAZQ Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Topotecan + Fulvestrant DC35OJD Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Topotecan + Fulvestrant DC2119F Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Topotecan + Fulvestrant DCRDIFZ Topotecan Prostate carcinoma (Cell Line: PC-3) [4]
Topotecan + Fulvestrant DCSPNZJ Topotecan Renal cell carcinoma (Cell Line: SN12C) [4]
Triapine + Fulvestrant DCXUHHO Triapine Invasive ductal carcinoma (Cell Line: T-47D) [2]
Triapine + Fulvestrant DC7B93F Triapine Clear cell renal cell carcinoma (Cell Line: A498) [4]
Triapine + Fulvestrant DCIH9FK Triapine Glioblastoma (Cell Line: SNB-75) [4]
Triapine + Fulvestrant DC3GYHI Triapine Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Trifluridine + Fulvestrant DCS7ZQE Trifluridine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Trifluridine + Fulvestrant DCL0Y3D Trifluridine Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Fulvestrant DCGUPTC Vandetanib Carcinoma (Cell Line: MCF7) [2]
Vandetanib + Fulvestrant DCDUF6C Vandetanib Colon adenocarcinoma (Cell Line: COLO 205) [2]
Vandetanib + Fulvestrant DC4R0ZO Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [2]
Vandetanib + Fulvestrant DCB1U7K Vandetanib Adenocarcinoma (Cell Line: OVCAR3) [4]
Vandetanib + Fulvestrant DCBWOAU Vandetanib Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Fulvestrant DCCBN2E Vandetanib Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Fulvestrant DCEYZ4F Vandetanib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Fulvestrant DCQHW3J Vandetanib Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Fulvestrant DCOL5O1 Vandetanib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Fulvestrant DCC073A Vandetanib Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Fulvestrant DCOYMGG Vandetanib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Fulvestrant DCS8OS3 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Fulvestrant DCMGQ0Q Vandetanib Glioma (Cell Line: SF-268) [4]
Vandetanib + Fulvestrant DCAQW3W Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vandetanib + Fulvestrant DC6WD7X Vandetanib Melanoma (Cell Line: UACC-257) [4]
Vandetanib + Fulvestrant DCZNHES Vandetanib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Fulvestrant DCE5R9T Vandetanib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vemurafenib + Fulvestrant DCUFP8H Vemurafenib Carcinoma (Cell Line: MCF7) [2]
Vemurafenib + Fulvestrant DCDU9UY Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [2]
Vemurafenib + Fulvestrant DCQNFH2 Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [2]
Vemurafenib + Fulvestrant DCYNGH2 Vemurafenib Adenocarcinoma (Cell Line: OVCAR3) [4]
Vemurafenib + Fulvestrant DCI23PE Vemurafenib Adenocarcinoma (Cell Line: HT29) [4]
Vemurafenib + Fulvestrant DCNK460 Vemurafenib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vemurafenib + Fulvestrant DCIUKMQ Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vemurafenib + Fulvestrant DCWCHQI Vemurafenib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vemurafenib + Fulvestrant DCGYL45 Vemurafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vemurafenib + Fulvestrant DCCMG0L Vemurafenib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vemurafenib + Fulvestrant DC8N57J Vemurafenib Glioma (Cell Line: SF-268) [4]
Vemurafenib + Fulvestrant DCOG6IX Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vemurafenib + Fulvestrant DCHTUK6 Vemurafenib Lung adenocarcinoma (Cell Line: EKVX) [4]
Vemurafenib + Fulvestrant DCPSFC2 Vemurafenib Melanoma (Cell Line: MALME-3M) [4]
Vemurafenib + Fulvestrant DC841VL Vemurafenib Melanoma (Cell Line: SK-MEL-2) [4]
Vemurafenib + Fulvestrant DCSJ8CY Vemurafenib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vemurafenib + Fulvestrant DCA0SWB Vemurafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vemurafenib + Fulvestrant DCL3TPN Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vemurafenib + Fulvestrant DCOPDNR Vemurafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vincristine + Fulvestrant DCGCB29 Vincristine Adenocarcinoma (Cell Line: DU-145) [3]
Vincristine + Fulvestrant DCGPNNU Vincristine Adenocarcinoma (Cell Line: HT29) [3]
Vincristine + Fulvestrant DC27QD6 Vincristine Adenocarcinoma (Cell Line: HCT116) [3]
Vincristine + Fulvestrant DC8PSXB Vincristine Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Vincristine + Fulvestrant DC5SR63 Vincristine Glioma (Cell Line: SF-295) [3]
Vincristine + Fulvestrant DCHSV6O Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Vincristine + Fulvestrant DCH82IB Vincristine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Vincristine + Fulvestrant DC981IX Vincristine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Vincristine + Fulvestrant DCML5Q0 Vincristine Prostate carcinoma (Cell Line: PC-3) [3]
Vincristine + Fulvestrant DCWU5YO Vincristine Renal cell carcinoma (Cell Line: UO-31) [3]
Vincristine + Fulvestrant DCRU2DN Vincristine Breast adenocarcinoma (Cell Line: MDA-MB-468) [2]
Vincristine + Fulvestrant DCTSG8L Vincristine Colon adenocarcinoma (Cell Line: COLO 205) [2]
Vincristine + Fulvestrant DCYWNEF Vincristine Invasive ductal carcinoma (Cell Line: T-47D) [2]
Vinflunine + Fulvestrant DC2PV44 Vinflunine Breast adenocarcinoma (Cell Line: MDA-MB-468) [2]
Vinflunine + Fulvestrant DCTZ2IN Vinflunine Invasive ductal carcinoma (Cell Line: T-47D) [2]
Vinflunine + Fulvestrant DCKVVFE Vinflunine Adenocarcinoma (Cell Line: A549) [4]
Vinflunine + Fulvestrant DCC6NEN Vinflunine Adenocarcinoma (Cell Line: HCC-2998) [4]
Vinflunine + Fulvestrant DC9SE5L Vinflunine Melanoma (Cell Line: SK-MEL-2) [4]
Vinflunine + Fulvestrant DCC515A Vinflunine Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vismodegib + Fulvestrant DCEY6UC Vismodegib Carcinoma (Cell Line: MCF7) [2]
Vismodegib + Fulvestrant DCJU6QW Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [2]
Vismodegib + Fulvestrant DC23P30 Vismodegib Invasive ductal carcinoma (Cell Line: HS 578T) [2]
Vismodegib + Fulvestrant DCXBMDM Vismodegib Adenocarcinoma (Cell Line: DU-145) [4]
Vismodegib + Fulvestrant DC5954X Vismodegib Adenocarcinoma (Cell Line: HT29) [4]
Vismodegib + Fulvestrant DC0MR8Q Vismodegib Adenocarcinoma (Cell Line: HCT-15) [4]
Vismodegib + Fulvestrant DCUZU51 Vismodegib Adenocarcinoma (Cell Line: HCC-2998) [4]
Vismodegib + Fulvestrant DCDO6DT Vismodegib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vismodegib + Fulvestrant DCUZM6F Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vismodegib + Fulvestrant DCLYHWL Vismodegib Amelanotic melanoma (Cell Line: M14) [4]
Vismodegib + Fulvestrant DCCIA5P Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vismodegib + Fulvestrant DCBILN2 Vismodegib Glioma (Cell Line: SF-268) [4]
Vismodegib + Fulvestrant DC0DAKV Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vismodegib + Fulvestrant DCA1C2R Vismodegib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vismodegib + Fulvestrant DCZFCER Vismodegib Melanoma (Cell Line: UACC-257) [4]
Vismodegib + Fulvestrant DC6Z7NT Vismodegib Melanoma (Cell Line: SK-MEL-2) [4]
Vismodegib + Fulvestrant DC9QSPD Vismodegib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vismodegib + Fulvestrant DC3HLOK Vismodegib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vismodegib + Fulvestrant DCKQTIP Vismodegib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 522 DrugCom(s)
62 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Fulvestrant + LY2835219 DC0DGRR LY2835219 Advanced Cancer [5]
Fulvestrant + HKI-272 DC1FI0Q HKI-272 Breast Neoplasms [6]
Fulvestrant + Buparlisib DC3EXII Buparlisib Estrogen Receptor-positive Breast Cancer [7]
Fulvestrant + Zarnestra DC3JY46 Zarnestra Estrogen Receptor-positive Breast Cancer [8]
Fulvestrant + Anastrozole DC3MS0U Anastrozole Breast Cancer [9]
Fulvestrant + Bortezomib DC4REU9 Bortezomib Metastatic Breast Carcinoma [10]
Fulvestrant + Exemestane DC5HU7A Exemestane Breast Cancer [11]
Fulvestrant + Everolimus DC5OHFG Everolimus Breast Cancer [12]
Fulvestrant + GDC0941 DC6KKOZ GDC0941 Breast Cancer [13]
Fulvestrant + Erlotinib DCCGXQX Erlotinib Stage IV Lung Cancer [14]
Fulvestrant + Enzastaurin DCDIBHO Enzastaurin Breast Cancer [15]
Fulvestrant + Gefitinib DCFS5CS Gefitinib Stage IV Lung Cancer [14]
Fulvestrant + GDC-0980/RG7422 DCKNLWO GDC-0980/RG7422 Breast Cancer [13]
Fulvestrant + GDC-0032 DCKZ7CR GDC-0032 Solid Cancers [16]
Fulvestrant + Capecitabine DCL8ASK Capecitabine Metastatic Breast Cancer [17]
Fulvestrant + Letrozole DCLJLDI Letrozole Breast Cancer [18]
Fulvestrant + Cabozantinib DCMHKI2 Cabozantinib Breast Cancer [19]
Fulvestrant + Gefitinib DCQXZ21 Gefitinib Estrogen Receptor-positive Breast Cancer [20]
Fulvestrant + Erlotinib DCQZ7IC Erlotinib Lung Cancer [21]
Fulvestrant + Everolimus DCR7VGL Everolimus Metastatic Breast Cancer [22]
Fulvestrant + Dasatinib DCRJZ0O Dasatinib Advanced Breast Cancer [23]
Fulvestrant + Selumetinib DCV9ER8 Selumetinib Breast Cancer [24]
Fulvestrant + Enzalutamide DCW7X3C Enzalutamide Breast Cancer [25]
Fulvestrant + Alpelisib DC1WHOV Alpelisib Breast Cancer [26]
Fulvestrant + Tucatinib DC24EA7 Tucatinib Anatomic Stage II Breast Cancer AJCC v8 [27]
Fulvestrant + Buparlisib DC2YQEC Buparlisib Breast Cancer [26]
Fulvestrant + Tucatinib DCMDIAN Tucatinib HER2-positive Metastatic Breast Cancer [28]
Fulvestrant + AZD5363 DC5BWJ0 AZD5363 Estrogen Receptor Positive Breast Cancer [29]
Fulvestrant + GDC-0068 DCSUCHX GDC-0068 Breast Cancer [30]
Fulvestrant + LEE011 DCW30QW LEE011 Breast Cancer [26]
Fulvestrant + LY2835219 DCR3Q0K LY2835219 Anatomic Stage IV Breast Cancer AJCC v8 [31]
Fulvestrant + LY2835219 DC9JUZ2 LY2835219 Breast Cancer [32]
Fulvestrant + Palbociclib DCDAWVA Palbociclib Metastatic Breast Carcinoma [33]
Fulvestrant + LY2835219 DCJSKSZ LY2835219 Breast Cancer Metastatic [34]
Fulvestrant + Goserelin DCV8UQ1 Goserelin Advanced Breast Cancer [35]
Fulvestrant + Alpelisib DCXNTQ2 Alpelisib Breast Cancer [36]
Fulvestrant + Azacitidine DC339GI Azacitidine Breast Neoplasms [37]
Fulvestrant + Vandetanib DC4REQD Vandetanib Neoplasms [38]
Fulvestrant + Sapanisertib DC5O2AR Sapanisertib Breast Cancer [39]
Fulvestrant + Palbociclib DC6LL1C Palbociclib Metastatic Breast Cancer [40]
Fulvestrant + HKI-272 DC6U7W7 HKI-272 Stage IV (Metastatic) Breast Cancer [41]
Fulvestrant + Venetoclax DCESOVP Venetoclax Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer [42]
Fulvestrant + Alpelisib DCG8FJE Alpelisib Breast Cancer [43]
Fulvestrant + Enzalutamide DCG8LKC Enzalutamide Breast Cancer [44]
Fulvestrant + Docetaxel DCGHK79 Docetaxel Metastatic Breast Cancer [45]
Fulvestrant + Regorafenib DCGVKYC Regorafenib Ovarian Cancer [46]
Fulvestrant + Olaparib DCHL5X7 Olaparib Advanced Breast Cancer [47]
Fulvestrant + Arry-162 DCIOVZW Arry-162 Anatomic Stage IV Breast Cancer AJCC v8 [48]
Fulvestrant + Palbociclib DCIR35B Palbociclib Estrogen Receptor Positive [49]
Fulvestrant + Goserelin DCN2LA7 Goserelin Metastatic Breast Cancer [50]
Fulvestrant + Bay 80-6946 DCQ1NVR Bay 80-6946 Endometrial Cancer [51]
Fulvestrant + SNDX-275 DCVF159 SNDX-275 Breast Cancer [52]
Fulvestrant + MK-4827 DCVL6DQ MK-4827 Breast Cancer [53]
Fulvestrant + Exemestane DCRTS97 Exemestane Breast Cancer [54]
Fulvestrant + Everolimus DC4RUW5 Everolimus Metastatic Breast Cancer [55]
Fulvestrant + Everolimus DC94AA9 Everolimus Advanced or Metastatic Breast Cancer [56]
Fulvestrant + PF-05212384 DCDKVGD PF-05212384 Breast Cancer [57]
Fulvestrant + Everolimus DCHLNDL Everolimus Breast Cancer [58]
Fulvestrant + Lapatinib DC6BPFP Lapatinib Metastatic Breast Cancer [59]
Fulvestrant + Alpelisib DCCVL62 Alpelisib Breast Cancer [60]
Fulvestrant + PF-05212384 DCG6UGG PF-05212384 Breast Cancer [57]
Fulvestrant + LY2835219 DCVYG39 LY2835219 Breast Cancer [61]
------------------------------------------------------------------------------------
⏷ Show the Full List of 62 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1015).
2 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5 ClinicalTrials.gov (NCT01394016) A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
6 ClinicalTrials.gov (NCT01670877) Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
7 ClinicalTrials.gov (NCT01339442) BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
8 ClinicalTrials.gov (NCT00082810) Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
9 ClinicalTrials.gov (NCT00075764) S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
10 ClinicalTrials.gov (NCT01142401) Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
11 ClinicalTrials.gov (NCT00201864) Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
12 ClinicalTrials.gov (NCT00570921) Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
13 ClinicalTrials.gov (NCT01437566) Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
14 ClinicalTrials.gov (NCT01556191) Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
15 ClinicalTrials.gov (NCT00451555) Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
16 ClinicalTrials.gov (NCT01296555) A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
17 ClinicalTrials.gov (NCT00534417) Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
18 ClinicalTrials.gov (NCT00545077) Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
19 ClinicalTrials.gov (NCT01441947) Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
20 ClinicalTrials.gov (NCT00057941) Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
21 ClinicalTrials.gov (NCT00100854) Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
22 ClinicalTrials.gov (NCT01797120) Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
23 ClinicalTrials.gov (NCT00754325) Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
24 ClinicalTrials.gov (NCT01160718) Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
25 ClinicalTrials.gov (NCT01597193) Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
26 ClinicalTrials.gov (NCT02088684) Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
27 ClinicalTrials.gov (NCT05319873) Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
28 ClinicalTrials.gov (NCT05230810) Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
29 ClinicalTrials.gov (NCT01992952) Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
30 ClinicalTrials.gov (NCT03959891) AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
31 ClinicalTrials.gov (NCT04256941) Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
32 ClinicalTrials.gov (NCT05524584) Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
33 ClinicalTrials.gov (NCT02778685) Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
34 ClinicalTrials.gov (NCT04603183) ABemaciclib, ET paclItaxel in aGgressive HR+/HER2- MBC trIaL
35 ClinicalTrials.gov (NCT04862143) Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
36 ClinicalTrials.gov (NCT05090358) Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
37 ClinicalTrials.gov (NCT02374099) Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
38 ClinicalTrials.gov (NCT02530411) Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
39 ClinicalTrials.gov (NCT02049957) Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer. U.S. National Institutes of Health.
40 ClinicalTrials.gov (NCT02491983) Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
41 ClinicalTrials.gov (NCT04901299) Fulvestrant + Neratinib In Breast Cancer
42 ClinicalTrials.gov (NCT03584009) A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
43 ClinicalTrials.gov (NCT03056755) Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
44 ClinicalTrials.gov (NCT02955394) Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
45 ClinicalTrials.gov (NCT02137083) A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
46 ClinicalTrials.gov (NCT05113368) Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
47 ClinicalTrials.gov (NCT05536128) Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
48 ClinicalTrials.gov (NCT05554354) Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
49 ClinicalTrials.gov (NCT03377101) Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
50 ClinicalTrials.gov (NCT02072512) The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
51 ClinicalTrials.gov (NCT05082025) Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
52 ClinicalTrials.gov (NCT02115594) Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
53 ClinicalTrials.gov (NCT05601440) Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
54 ClinicalTrials.gov (NCT06016738) OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
55 ClinicalTrials.gov (NCT02404051) Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
56 ClinicalTrials.gov (NCT06105632) A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
57 ClinicalTrials.gov (NCT05501886) Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
58 ClinicalTrials.gov (NCT02137837) S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
59 ClinicalTrials.gov (NCT02394496) Overcoming Endocrine Resistance in Metastatic Breast Cancer
60 ClinicalTrials.gov (NCT02437318) Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
61 ClinicalTrials.gov (NCT02763566) A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer